Loading
A phase 2 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Fujifilm Pharmaceuticals U.S.A., Inc., active and no longer recruiting.
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05318573 by Fujifilm Pharmaceuticals U.S.A., Inc., with 120 participants planned, started 2022-06-01 and due to reach its primary completion in 2029-05. Interventions recorded: Pembrolizumab, FF-10832. Conditions listed: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.